IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza and Teva discontinue biosimilars joint venture

12:00 AM MDT | July 25, 2013 | Deepti Ramesh

Lonza and Teva Pharmaceutical Industries (PetaŠł• Tiqwa, Israel) today said that, following a strategic review, they have decided to discontinue the previously announced collaboration for the development, manufacturing, and marketing of biosimilars. Lonza and Teva had agreed, in 2009, to establish the biosimilars jv. Biosimilars are approved versions of innovator biopharmaceutical products, made after patent expiry of the innovator product. Doubts were raised about the future of the jv after Lonza CEO Richard Ridinger, in an interview with a Swiss business...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa